RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells
Authors
Keywords
-
Journal
CARCINOGENESIS
Volume 35, Issue 12, Pages 2807-2814
Publisher
Oxford University Press (OUP)
Online
2014-10-17
DOI
10.1093/carcin/bgu210
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia
- (2013) K. A. Urtishak et al. BLOOD
- Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma
- (2013) Wei-Tien Tai et al. HEPATOLOGY
- BCL-2 Inhibitors Sensitize Therapy-resistant Chronic Lymphocytic Leukemia Cells to VSV Oncolysis
- (2013) Sara Samuel et al. MOLECULAR THERAPY
- A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
- (2012) A A Chiappori et al. BRITISH JOURNAL OF CANCER
- A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation
- (2012) Kuen-Feng Chen et al. CANCER LETTERS
- Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells
- (2012) Jie Yang et al. CANCER LETTERS
- Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists
- (2012) Jung-Chen Su et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Regulatory Factor X1-induced Down-regulation of Transforming Growth Factor β2 Transcription in Human Neuroblastoma Cells
- (2012) Chenzhuo Feng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3
- (2011) Runqiu Jiang et al. HEPATOLOGY
- Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
- (2011) Wei-Tien Tai et al. JOURNAL OF HEPATOLOGY
- Breast Cancer Cells Proliferation Is Regulated by Tyrosine Phosphatase SHP1 through c-jun N-Terminal Kinase and Cooperative Induction of RFX-1 and AP-4 Transcription Factors
- (2011) S. Amin et al. MOLECULAR CANCER RESEARCH
- Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3
- (2011) W.-T. Tai et al. MOLECULAR CANCER THERAPEUTICS
- Study of FoxA Pioneer Factor at Silent Genes Reveals Rfx-Repressed Enhancer at Cdx2 and a Potential Indicator of Esophageal Adenocarcinoma Development
- (2011) Jason A. Watts et al. PLoS Genetics
- Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
- (2010) K.-F. Chen et al. CLINICAL CANCER RESEARCH
- Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells
- (2010) Yan Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation ofFGF1Gene Promoter through Transcription Factor RFX1
- (2010) Yi-Chao Hsu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
- (2009) C. Verslype et al. ANNALS OF ONCOLOGY
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells
- (2008) K. Nakase et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1
- (2008) M. K. Pandey et al. MOLECULAR PHARMACOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now